Immune checkpoint inhibitor was undoubtedly a breakthrough in cancer therapy. Since FDA approved Pembrolizumab and Nivolumab for melanoma in 2014, PD-1/PD-L1 blockade has been proven to be effective in multiple cancers including lung, head and neck, kidney, breast, bladder cancer, and lymphoma.
